CinCor Pharma, Inc., (CINC): Price and Financial Metrics Recent IPO


CinCor Pharma, Inc., (CINC): $19.03

2.16 (+12.80%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CINC to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CINC Stock Price Chart Interactive Chart >

Price chart for CINC

CINC Price/Volume Stats

Current price $19.03 52-week high $30.66
Prev. close $16.87 52-week low $13.00
Day low $16.76 Volume 563,800
Day high $19.55 Avg. volume 178,777
50-day MA $19.34 Dividend yield N/A
200-day MA $0.00 Market Cap 717.62M

CinCor Pharma, Inc., (CINC) Company Bio


CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardiovascular diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension and primary aldosteronism, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.


CINC Latest News Stream


Event/Time News Detail
Loading, please wait...

CINC Latest Social Stream


Loading social stream, please wait...

View Full CINC Social Stream

Latest CINC News From Around the Web

Below are the latest news stories about CinCor Pharma Inc that investors may wish to consider to help them evaluate CINC as an investment opportunity.

Wall Street gyrations may thwart deal closings, IPO outlook

In terms of doing mergers and acquisitions and raising money through initial public offerings, 2021 was huge. But 2022 may be vastly different.

Yahoo | January 27, 2022

CinCor Pharma Appoints June Lee to Its Board of Directors

BOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced the appointment of the independent member June Lee, M.D. to the company’s Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnology and pharmaceutical industry and has served in numerous executive and board roles. “We are very pleased to welcome June to the CinCor Board,” said James Healy, M.D., Ph.D., Chairman of CinCor’s Board of Directors. “As the Company’s clinical prog

Yahoo | January 13, 2022

10 Best Stocks to Buy on the Nasdaq Right Now

When you’re looking for stocks to buy there are so many things you can take into account, but starting with looking at the markets themselves is a good tactic. With such a blistering performance in the benchmark indices throughout most of the post-pandemic months, it may have been inevitable that a correction would occur. Just like the real world, investor sentiment features a gravitational pull: nothing can go up forever. Having said that, not all indices have suffered equally, presenting a con

Yahoo | January 13, 2022

CinCor Pharma's stock opens well above IPO price, then sells off sharply

CinCor Pharma Inc.'s stock shot out of the gate in morning trading Friday, but then pulled back sharply, to trade briefly below in negative territory. The Massachusetts-based biopharmaceutical company's stock's first trade was at $21.00 at 11:05 a.m. Eastern, or 31.3% above the $16 IPO price. The stock then rose to an intraday high of $22.67, before selling off to trade as low as $15.69, or 1.9% below its IPO price, before bouncing slightly to trade flat. At current prices, the company is valued

Yahoo | January 7, 2022

CinCor Pharma raised $194 million as upsized IPO prices in middle of expected range

CinCor Pharma Inc. is set to go public on the Nasdaq Friday, after the Massachusetts-based biopharmaceutical company's upsized initial public offering priced overnight at $16 a share, in the middle of the expected range of between $15 and $17 a share. The company raised $193.6 million as it sold 12.1 million shares in the IPO, up from previous expectations of an 11.0 million share offering. The IPO pricing values the company at about $566.7 million. Morgan Stanley, Jefferies and Evercore ISI are

Yahoo | January 7, 2022

Read More 'CINC' Stories Here

CINC Price Returns

1-mo 15.05%
3-mo -3.94%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5282 seconds.